JP2023551009A5 - - Google Patents
Info
- Publication number
- JP2023551009A5 JP2023551009A5 JP2023532513A JP2023532513A JP2023551009A5 JP 2023551009 A5 JP2023551009 A5 JP 2023551009A5 JP 2023532513 A JP2023532513 A JP 2023532513A JP 2023532513 A JP2023532513 A JP 2023532513A JP 2023551009 A5 JP2023551009 A5 JP 2023551009A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- composition according
- pp6m
- paliperidone palmitate
- pp3m
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119363P | 2020-11-30 | 2020-11-30 | |
| US63/119,363 | 2020-11-30 | ||
| PCT/EP2021/062198 WO2022111860A1 (en) | 2020-11-30 | 2021-05-07 | Dosing regimens associated with extended release paliperidone injectable formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551009A JP2023551009A (ja) | 2023-12-06 |
| JP2023551009A5 true JP2023551009A5 (enExample) | 2024-05-17 |
Family
ID=75904921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532513A Pending JP2023551009A (ja) | 2020-11-30 | 2021-05-07 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11439647B2 (enExample) |
| EP (1) | EP4025189B1 (enExample) |
| JP (1) | JP2023551009A (enExample) |
| KR (1) | KR20230116836A (enExample) |
| CN (1) | CN116528836A (enExample) |
| AU (1) | AU2021389587A1 (enExample) |
| CA (1) | CA3203015A1 (enExample) |
| DK (1) | DK4025189T3 (enExample) |
| ES (1) | ES2981035T3 (enExample) |
| FI (1) | FI4025189T3 (enExample) |
| HR (1) | HRP20240800T1 (enExample) |
| HU (1) | HUE067072T2 (enExample) |
| IL (1) | IL303252A (enExample) |
| LT (1) | LT4025189T (enExample) |
| MX (1) | MX2023006368A (enExample) |
| PL (1) | PL4025189T3 (enExample) |
| RS (1) | RS65815B1 (enExample) |
| TW (1) | TW202222317A (enExample) |
| WO (1) | WO2022111860A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4005555T3 (pl) | 2020-11-30 | 2024-09-02 | Janssen Pharmaceutica Nv | Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu |
| SI4025187T1 (sl) | 2020-11-30 | 2024-03-29 | Janssen Pharmaceutica Nv | Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem |
| CN116528836A (zh) | 2020-11-30 | 2023-08-01 | 詹森药业有限公司 | 与延长释放帕潘立酮可注射制剂相关的给药方案 |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| CN101163702B (zh) | 2005-04-25 | 2011-09-07 | 詹森药业有限公司 | 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法 |
| CA2655335C (en) | 2007-12-19 | 2016-09-06 | Janssen Pharmaceutica N.V. | Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| AU2010313290A1 (en) * | 2009-10-30 | 2012-05-17 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
| SI2529757T1 (sl) | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
| WO2016157061A1 (en) | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| DK3744326T3 (da) * | 2015-04-07 | 2024-02-05 | Janssen Pharmaceutica Nv | Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere |
| US20190183896A1 (en) | 2017-12-14 | 2019-06-20 | SpecGx LLC | One step milling process for preparing micronized paliperidone esters |
| EP4025188B1 (en) | 2020-11-30 | 2024-01-10 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
| CN116528836A (zh) | 2020-11-30 | 2023-08-01 | 詹森药业有限公司 | 与延长释放帕潘立酮可注射制剂相关的给药方案 |
| SI4025187T1 (sl) | 2020-11-30 | 2024-03-29 | Janssen Pharmaceutica Nv | Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem |
| PL4005555T3 (pl) | 2020-11-30 | 2024-09-02 | Janssen Pharmaceutica Nv | Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
-
2021
- 2021-05-07 CN CN202180080431.1A patent/CN116528836A/zh active Pending
- 2021-05-07 DK DK21725105.7T patent/DK4025189T3/da active
- 2021-05-07 US US17/314,245 patent/US11439647B2/en active Active
- 2021-05-07 KR KR1020237021404A patent/KR20230116836A/ko active Pending
- 2021-05-07 RS RS20240853A patent/RS65815B1/sr unknown
- 2021-05-07 ES ES21725105T patent/ES2981035T3/es active Active
- 2021-05-07 IL IL303252A patent/IL303252A/en unknown
- 2021-05-07 TW TW110116511A patent/TW202222317A/zh unknown
- 2021-05-07 HU HUE21725105A patent/HUE067072T2/hu unknown
- 2021-05-07 CA CA3203015A patent/CA3203015A1/en active Pending
- 2021-05-07 HR HRP20240800TT patent/HRP20240800T1/hr unknown
- 2021-05-07 JP JP2023532513A patent/JP2023551009A/ja active Pending
- 2021-05-07 PL PL21725105.7T patent/PL4025189T3/pl unknown
- 2021-05-07 EP EP21725105.7A patent/EP4025189B1/en active Active
- 2021-05-07 WO PCT/EP2021/062198 patent/WO2022111860A1/en not_active Ceased
- 2021-05-07 AU AU2021389587A patent/AU2021389587A1/en not_active Abandoned
- 2021-05-07 LT LTEPPCT/EP2021/062198T patent/LT4025189T/lt unknown
- 2021-05-07 FI FIEP21725105.7T patent/FI4025189T3/fi active
- 2021-05-07 MX MX2023006368A patent/MX2023006368A/es unknown
-
2022
- 2022-09-09 US US17/941,464 patent/US12053474B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552329A5 (enExample) | ||
| JP3701870B2 (ja) | 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニ | |
| JP2023552149A5 (enExample) | ||
| US6312717B1 (en) | Method for treatment of anxiety and depression | |
| JP3623962B2 (ja) | ヒドロキソコバラミンの鼻中投与用医薬組成物 | |
| FI4025189T3 (fi) | Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia | |
| JP7594045B2 (ja) | 薬学的組成物 | |
| FI4025188T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| BR112012015202B1 (pt) | uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica | |
| JP2012533554A5 (enExample) | ||
| JP2023535744A5 (enExample) | ||
| AU618997B2 (en) | Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer | |
| FI4025187T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| JPH10158169A (ja) | 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法 | |
| US20230181704A1 (en) | Anti-sars-cov-2 virus agent antiprovir | |
| EA004474B1 (ru) | Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола | |
| JP2023543439A5 (enExample) | ||
| AU2006269628B2 (en) | Pharmaceutical formulations of endo-N-(9- methyl-9-azabicyclo[3 .3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride | |
| AU2011274652A1 (en) | A combination composition comprising ibuprofen and paracetamol | |
| Ananth et al. | Benztropine psychosis | |
| JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
| JPH0213644B2 (enExample) | ||
| EP1518554B1 (en) | Pharmaceutical composition for the treatment of hyperhomocysteinemia | |
| JPH0753388A (ja) | 骨代謝改善剤 | |
| HUP9903723A2 (hu) | Ginkgolidok alkalmazása membráneszpresszió gátlására |